Consolidated Statements of Equity (USD $)	Preferred Stock [Member]	Common Stock [Member]	Contingently Issuable Shares [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Restricted Preferred Stock [Member]	Additional Paid-In Capital [Member] Restricted Common Stock [Member]	Treasury Stock [Member]	Accumulated Deficit During Development Stage [Member]	Non-Controlling Interest In Subsidiary [Member]	Total	Restricted Preferred Stock [Member]	Restricted Common Stock [Member]
Balance at Dec. 31, 2010
Common stock issued to founders in exchange for seed capital in April 2011		$ 2,500		$ 104,078						$ 106,578
Common stock issued to founders in exchange for seed capital in April 2011 (in shares)		2,500,000
Stock issued at $2.25 per share in exchange for license option		132		296,868						297,000
Stock issued at $2.25 per share in exchange for license option (in shares)		132,000
Issuance of restricted stock		1,150								1,150
Issuance of restricted stock (in shares)		1,150,000
Effect of reverse acquisition	281	(2,501)	6	277,500					47,678	322,964
Effect of reverse acquisition (in shares)	281,250	(2,500,124)
Conversion of note payable to preferred stock	3			55,268						55,271
Conversion of note payable to preferred stock (in shares)	2,763
Issuance of replacement restricted preferred stock to employees	129	(1,150)		1,021						0
Issuance of replacement restricted preferred stock to employees (in shares)	129,375	(1,150,000)
Stock issued, net of expenses		4,930		9,650,886						9,655,816
Stock issued, net of expenses (in shares)		4,929,523
Compensation in respect of restricted stock granted to employees, directors and consultants					86,494						86,494
Net loss								(853,074)	(35,997)	(889,071)
Balance at Dec. 31, 2011	413	5,061	6	10,472,115				(853,074)	11,681	9,636,202
Balance (in shares) at Dec. 31, 2011	413,388	5,061,399
Issuance of restricted stock		5,902		(5,902)						0
Issuance of restricted stock (in shares)		5,901,743
Stock issued, net of expenses	696			12,180,710						12,181,406
Stock issued, net of expenses (in shares)	695,428
Compensation in respect of restricted stock granted to employees, directors and consultants					188,509	3,233,674					188,509	3,233,674
Shares issued in subsidiary to non-controlling interest in connection with in-licensing agreement									16,578,000	16,578,000
Conversion of preferred stock to common stock in conjunction with reverse stock split	(1,109)	9,858		(8,749)						0
Conversion of preferred stock to common stock in conjunction with reverse stock split (in shares)	(1,108,816)	9,857,596
Non-controlling interest subsidiary shares exchanged for shares in TG Therapeutics, Inc.		5,000		8,474,448					(8,479,448)	0
Non-controlling interest subsidiary shares exchanged for shares in TG Therapeutics, Inc. (in shares)		5,000,000
Surrender of common stock for tax withholding							(84,538)			(84,538)
Surrender of common stock for tax withholding (in shares)							13,526
Net loss								(18,072,719)	(8,110,233)	(26,182,952)
Balance at Dec. 31, 2012	$ 0	$ 25,821	$ 6	$ 34,534,805			$ (84,538)	$ (18,925,793)	$ 0	$ 15,550,301
Balance (in shares) at Dec. 31, 2012	0	25,820,738					13,526